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Abstract
Background: Pediatric inflammatory bowel disease (IBD) is challenging to diagnose because of the non-specificity of
symptoms; an unequivocal diagnosis can only be made using colonoscopy, which clinicians are reluctant to recommend for
children. Diagnosis of pediatric IBD is therefore frequently delayed, leading to inappropriate treatment plans and poor
outcomes. We investigated the use of 16S rRNA sequencing of fecal samples and new analytical methods to assess
differences in the microbiota of children with IBD and other gastrointestinal disorders.
Methodology/Principal Findings: We applied synthetic learning in microbial ecology (SLiME) analysis to 16S sequencing
data obtained from i) published surveys of microbiota diversity in IBD and ii) fecal samples from 91 children and young
adults who were treated in the gastroenterology program of Children’s Hospital (Boston, USA). The developed method
accurately distinguished control samples from those of patients with IBD; the area under the receiver-operating-
characteristic curve (AUC) value was 0.83 (corresponding to 80.3% sensitivity and 69.7% specificity at a set threshold). The
accuracy was maintained among data sets collected by different sampling and sequencing methods. The method identified
taxa associated with disease states and distinguished patients with Crohn’s disease from those with ulcerative colitis with
reasonable accuracy. The findings were validated using samples from an additional group of 68 patients; the validation test
identified patients with IBD with an AUC value of 0.84 (e.g. 92% sensitivity, 58.5% specificity).
Conclusions/Significance: Microbiome-based diagnostics can distinguish pediatric patients with IBD from patients with
similar symptoms. Although this test can not replace endoscopy and histological examination as diagnostic tools,
classification based on microbial diversity is an effective complementary technique for IBD detection in pediatric patients.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC), collectively
termed inflammatory bowel diseases (IBD), are incurable condi-
tions that cause ulceration of the intestinal mucosa. If left
untreated, IBD may require repeated surgical intervention to
remove affected parts of the gastrointestinal system [1] leading to
malabsorption and nutritional complications [2]. Despite its
importance, timely diagnosis is difficult because patients often
present with non-specific symptoms [3], and the presence of CD or
UC can only be confirmed by colonoscopy.
Diagnosis is particularly challenging in children, for whom
presenting symptoms may vary widely and may only consist of
subtle extra-intestinal manifestations [4]. This in turn leads to a
typical delay in the diagnosis of pediatric IBD, ranging from 4
weeks in severe colitis [5] to 6–7 months in milder disease [4].
Reducing this diagnostic delay is important, since a long period of
unmanaged symptoms can significantly impact growth [5] and
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39242early treatment is essential to preserving long-term quality of life
[6]. Thus a sensitive yet non-invasive detection tool, that could
identify patients at high risk for IBD, and therefore warranting
endoscopic evaluation, would be a valuable diagnostic aid.
Non-invasivetestsforIBD alreadyexist,includingantibodies[7],
imaging-basedscreens[8,9],andfecalbiomarkers[10].Specificities
for existing methods range from 89% to 95% for either CD or UC
[11], however,these methods are either limited to active disease,
poorly sensitive (,55%), or their outcome can be confounded by
diseases other than IBD [11], limiting their clinical utility [12,13].
The design of an accurate test for IBD is challenging, since the
precise cause of IBD is unknown. No single genetic, environmental
or epidemiological factor alone is diagnostic of IBD [14]. Instead,
current evidence about the aetiology of IBD points toward a
complex interplay between genetic, environmental, and immuno-
logical factors[15–17] and the intestinal microbiota[18–20].
Arguing in favour of the involvement of gut microbes in the
pathogenesis of IBD, it is known that colonisation with commensal
bacteria is required to elicit colitis in mice [19,21]. Similarly, in
IBD patients it is known that antibiotics can treat CD colitis in the
short term [22] and probiotics may prevent relapse of UC [23].
We hypothesized that changes in the intestinal microbiota,
whether causative of or responsive to disease, may provide a
viable diagnostic of disease status.
Previous microbial diversity studies have found characteristic
changes in the composition of the gut flora during IBD that could
potentially be used to screen patients with non-specific symptoms
[18,24].Inoneofthemostcomprehensivestudiestodate,Frankand
colleagues[24]mappedmicrobiotacompositionin124IBDandnon-
IBDpatientsbybiopsysamplingcoupledwith16SrRNAsequencing.
Theirworkshowedthatpatientswithalong-standinghistoryofIBD
had decreased levels of Firmicutes and increased level of Proteo-
bacteria, when compared to control individuals. While these results
firmlyestablishedtherelationshipbetweenGImicrobiotaanddisease
status, the overall approach is unsatisfactory as a diagnostic tool
because of low sensitivity (31%) and low overall accuracy (51%, as
determined from the third figure in[24]).
More recent studies have been able to accurately distinguish CD
and healthy individuals on the basis of pyrosequencing data [25],
but the same model was unable to distinguish UC from healthy
individuals or to differentiate patients in remission from patients
with active disease, raising questions about whether such
approaches show clinical potential. Finally, none of these studies
examined pediatric cohorts.
Here we demonstrate an approach that is capable of routinely
differentiating children with IBD from controls with other gastroin-
testinal diseases in a case-control study of ninety-one pediatric
patients.Ourmethodologyshowshighsensitivityandspecificityover
arangeofdiseaseprevalenceanditcanbeusedtoi)identifykeytaxa
associatedwitheachdiseasestate,ii)discriminateCDandUCandiii)
differentiatepatientswithactivediseasefromthoseinremission.We
confirmedourresultsbyblindvalidationwithanindependentcohort
of seventy-seven pediatric patients. This method applies next-
generation sequencing and robust statistical analysis using machine
learningtechniquesand,significantly,isatestforIBDbasedonnon-
invasive fecal sampling.
Results
Supervised Classification Distinguishes IBD and Non-IBD
Patients in Existing Tissue-based Studies
The case-control study of Frank and colleagues [24] used an
unsupervised clustering approach: principal components analysis
(PCA). When the class labels (healthy vs. diseased) are known for a
training set of samples, then supervised learning methods can also
be applied (e.g. support vector machines, random forests, etc.).
These algorithms have been widely and successfully applied to
many problems in the biomedical sciences [26,27,28] and their use
in a clinical setting is emerging in the analysis of gene expression
data [29,30,31,32] and microbiome data [33].
We first investigated whether supervised learning could offer
sufficient performance to be employed in a microbiota-based IBD
detection tool, by applying it to the published IBD data set of
Frank et al [24]. We employed our Synthetic Learning in
Microbial Ecology (SLiME) method to classify samples from the
existing data set as IBD or control. SLiME is a software pipeline
which applies supervised classification algorithm to sequencing
data, using associated metadata as the classification label.
Demultiplexed sequences are classified into lineages, clustered to
select a representative set and used to estimate the abundance of
each taxa in each sample. The resulting frequency table is
normalized and fed to a supervised classification algorithm.
SLiME is based on Random Forests (RFs) [34], which we chose
for its accuracy and speed, although we achieved similar results
using other supervised learning approaches such as bagging,
stacking and support vector machines (see Fig. S1). Applying
SLiME to the existing data set yielded accurate classification of
patients into IBD or non-IBD groups. Based on repeated ten-fold
cross validation, the area under the ROC curve (AUC) – which is
a measure of the overall accuracy of the classification algorithm
over the range of possible disease incidence [35] – was 0.73
(Fig. 1A). Choosing a cutoff on the curve which gives relatively
high sensitivity (ie. 87.6%) yields 47.3% specificity, amply
surpassing the accuracy of the clustering method originally
employed [24].
Supervised Classification Distinguishes IBD and Non-IBD
Pediatric Patients on the Basis of Stool
Although the results obtained using the existing Frank et al. [24]
data set were encouraging, there are several reasons why they
might not translate to a clinically useful diagnostic test. First,
samples were obtained invasively through surgical tissue resection
from adult patients with advanced disease, and may not reflect
changes observed in fecal samples from patients with less advanced
disease. Second, the control specimens in the Frank et al. study
were largely composed of tissue from cancer patients, and thus
were not typical of patients investigated for IBD in the pediatric
setting. We therefore designed a new case-control study to evaluate
whether fecal samples from children not undergoing surgery could
be utilized to differentiate between patients with and without IBD.
We selected a group of ninety-one children and young adults
receiving care in the gastroenterology program of Children’s
Hospital (Boston, USA), and obtained fecal samples. Of these
children, 23 had Crohn’s disease, 43 had ulcerative colitis, one had
undefined IBD (colitis with elements of CD and UC) and 24 had
non-IBD functional disease (patients with gastrointestinal symp-
toms but no intestinal inflammation). To evaluate the potential of
our method to differentiate between children with IBD and
children without IBD, we thought it essential to study not
completely healthy children, but children with gastrointestinal
symptoms. These are the children who would present to the
gastroenterologist for evaluation, and for whom IBD is in the
differential diagnosis. Demographics of the patient populations are
given in Table 1. We isolated DNA from the fecal samples and
sequenced a portion of the 16S rRNA gene using high throughput
454 pyrosequencing (see Materials and Methods). We then applied
SLiME to the resulting microbial compositional data.
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set despite the substitution of mucosal samples with stool samples,
yielding a ten-fold cross-validated AUC of 0.83 for distinguishing
IBD patients from controls (Fig. 1B). Sensitivity and specificity for
the diagnostic test can be obtained by selecting the desired
threshold along the curve. For instance, choosing a cutoff on the
curve at relatively high sensitivity (Fig. 1B, circle) yields 80.3%
sensitivity and 69.7% specificity for the test. The result is
particularly remarkable considering that fecal samples may not
be truly representative of the total intestinal microbiota. Indeed,
bacteria living in association with the intestinal epithelium, and
thus capable of interacting with innate immune receptors, are
likely not to be present in fecal samples.
The performance of the same classification algorithm was
higher when it was applied to distinguish from controls only those
IBD patients with clinically active disease, yielding an AUC of
0.91 (Fig. 1B dashed line). Table S6 and S7 show how the classifier
performs amongst the three disease groups (CD,UC and control)
at one arbitrary threshold. To test if the chosen sequencing
technology altered the classification of patients into controls and
IBD samples, we repeated sequencing for 10 of the samples using
the Sanger sequencing method. Supervised learning results,
however, were independent of the sequencing method employed
(Fig. S2). We hypothesized that some of the improvement in
performance might be due to increased sampling depth if a subset
of discriminatory bacteria are present at low abundance. To test
this hypothesis, we identified the bacterial taxa most strongly
associated with IBD (either positively or negatively), and plotted
their abundance. As shown in Fig. S3, many of the most
informative taxa are present at a level of less than 1% per sample
Figure 1. Accuracy of disease classification. (A) SLiME applied to
Frank et al. biopsy data set. The black line indicates performance
obtained when features were generated by taxonomical binning of the
original sequence data (AUC =0.73); dashed line shows performance
when features were selected based on their importance in the pediatric
case-control data set and then applied to the Frank et al. study (AUC
=0.71). (B) ROC curve for SLiME classification of active IBD patients vs
controls in the pediatric case-control data set. Two different threshold
selections are highlighted: circle, for which SLiME has 80.3% sensitivity
and 69.7% specificity; triangle, for which SLiME has 45.8% sensitivity
and 92.4% specificity.
doi:10.1371/journal.pone.0039242.g001
Table 1. demographics of paediatric (training) cohort.
Crohn’s UC Control IBDU
n2 3 4 3 2 4 1
Gender Male 13(56%) 21(49%) 10(42.%) 1
Female 10(44%) 22(51%) 14(58%) 0
Age Median +/2 s.d. 14.1363.84 13.764.25 9.0864.3 14
Range 3–20 4–24 3–17
Montreal
class.
L1 1(4%)
L2 1(4%)
L3 15(65%)
L4 6(26%)
B1 18(78%)
B2 4(17%)
B3 1(4%)
E1 2(5%)
E2 6(14%)
E3 35(81%)
Disease
Activity
Control 0 0 24 0
Inactive 14 11
Mild 51 5 1
Moderate 39
Severe 18
Medications Salicylates only 1 (4%) 6(14%)
6mp/AZA/MTX 11 (48%) 12(28%)
Anti-TNF 7 (30%) 4(9%)
Calcineurin
inhibitor
0 23(53%)
Antibiotics 6 (26%) 14(33%) 1
(Steroids) 13 (57%) 25(58%) 1
doi:10.1371/journal.pone.0039242.t001
Pediatric IBD Detection by Microbiome Mapping
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39242– the level at which we would expect to see one count or less at the
sequencing depth used in Frank et al [24]. Thus, sequencing depth
is an important factor in diagnostic accuracy and may account to a
large degree for the lower AUC we obtained in the classification of
the Frank et al. data set.
Distinctive Taxonomical Groups are Associated with IBD
We identified a number of bacterial taxa strongly associated
with IBD that both confirmed and supplemented previous studies.
Fig. 2 shows taxa that are significantly associated with either IBD
or control patients (q-value ,0.01, Kruskal-Wallis test, FDR
adjusted [36], E(p0)=0.18, see Fig. S4). Only a few of these taxa
show a distribution consistent with an ideal microbial biomarker –
a bacterial group whose presence/absence indicates disease
phenotype. For example, the Enterobacteriales are indicators of
active IBD (ie. patients with clinically active disease and not in
remission), while Rikenellaceae and Porphyromonadaceae are
generally found within the control group. By contrast, most of the
discriminatory groups in Fig. 2 are more or less abundant in IBD
patients, but not exclusive to one population (e.g., the Butyr-
icicoccus and Subdoligranum genera decrease in the IBD patients
with clinically active disease, but are still present in some IBD
patients with inactive disease). This highlights the need for
quantitative global surveys of microbial diversity rather than
simple indicators of presence/absence.
Microbial Alterations are Similar in Stool and Tissue
Samples
Our finding that classification was similarly accurate in tissue
and stool samples led us to ask whether the same alterations in the
gut profile were observed in both sample types or whether distinct
but similarly predictive changes occurred in each. To test this, we
used the bacterial taxa identified in the pediatric case-control
(stool-based) study to re-classify the tissue samples in the study by
Frank et al. [24] The classification accuracy based on features
from the pediatric study was nearly identical to the model using
features picked from the tissue-based study: AUC =0.71 (Fig. 1A),
an increase in estimated measurement error of only 3%.
The relative change (upwards or downwards) of taxa in IBD
vs. control groups is remarkably concordant between the two
studies, with the exception of Lactobacillales (Fig. 3). Unsurpris-
ingly, due to the largely different sequencing depth many of the
low-abundance taxa detected in the pediatric case-control (e.g.,
Alistipes) are of little importance in the classification, when
applied to the Frank et al. data (Fig. S5). On the other hand, the
Subdoligranulum genus and the Proteobacteria phylum remain
two consistently important features across data sets (Fig. 3).
These results are encouraging because they suggest stool samples
can be used to study changes in other compartments such as the
mucosa.
Microbiota Diversity Decreases as Disease Severity
Increases
An important clinical question is to establish whether a marker
of disease activity exists, and to what extent it can be used to
stratify patients according to disease severity. To address this
question, we measured disease activity by means of standard
clinical indices (PUCAI [37], PCDAI [38]), based on symptoms
and blood test results [39], and compared to SLiME predictions.
While SLiME could not reliably classify on the basis of activity due
to the small number of patients in each distinct level of disease
severity, we nevertheless observed that overall microbiota diversity
was strongly associated with disease activity. As disease severity
increased, independently of the type of disease (CD or UC), overall
bacterial diversity decreased as measured by the Shannon diversity
index (Fig. 4). These results further support the view that IBD
reflects an overall GI tract dysbiosis rather than the effect of a
small number of pathogenic taxa [20,24,40]. Moreover, a number
of microbial taxa showed significant association with disease
activity levels. Among the most discriminative taxa was the
Proteobacteria phylum (Fig. 5, see also Fig. S6). Specifically, the
Gammaproteobacteria class was prevalent in all active forms of the
disease. Severe disease in particular was associated with the
Serratia and Escherichia-Shigella genera as well as the Coryneo-
bacteriacea family.
Gut Microbiota Shows Characteristic Changes from
Active Disease to Remission
The factors responsible for triggering episodes of active disease
are largely unknown. To identify microbial groups potentially
associated with the establishment of active disease, we compared
the composition of bacteria in fecal samples taken during active
disease and remission periods. Classification with SLiME could
distinguish between active and remission samples with an AUC of
0.72. Amongst the taxa which were significantly associated with
active disease (Fig. S7) we found Proteobacteria (q-value ,0.05,
Kruskal-Wallis test, FDR adjusted [36], E(p0)=0.35, see Fig. S8)
which was in agreement with previous observations [41]. This
finding appears to confirm the hypothesis that before or during
active disease Proteobacteria rapidly expand and potentially
displace other bacterial groups, such as Actinobacteria. On the
other hand, members of the Eubacteriaceae, Incertae Sedis XIV
and Bifidobacteriaceae families were associated with remission,
which to our knowledge has not been reported previously. The
Lachnospiraceae family, Subdoligranulum and Butyricicoccus, a
butyrate-producing organism that can ferment dietary polysac-
charides, were also associated with remission.
Diversity is Correlated with Antibiotic Therapy
We found that overall microbial diversity, as measured by the
Shannon diversity index, was the single most important feature for
discriminating between patients undergoing antibiotic therapy or
not. Although we could not classify whether samples were
obtained from antibiotic-treated patients with high accuracy
(AUC ,0.6), we did find that Shannon diversity index was
significantly and negatively associated with antibiotic therapy in
the IBD samples (p-value =0.0067, Wilcoxon test, see Fig. S9).
This observation is consistent with a simple model of antibiotic
effect on the gut microbiota: most taxa and bacterial groups are
killed by antibiotics, while the few bacterial strains which have
resistance survive and increase in relative abundance.
Differential Diagnosis of Ulcerative Colitis and Crohn’s
Disease is Possible
Ulcerative colitis is generally limited to the colon, while
intestinal inflammation in Crohn’s disease may occur in any
region of the gastrointestinal tract. Classification of pediatric IBD
patients into UC or CD at the time of fecal testing is desirable,
given the different clinical management of the two diseases. Even
though distinguishing UC from CD was not the primary aim of
our study design, we found that SLiME applied to the case-control
data set could separate UC patients and control patients (Fig. 6A,
cross-validated AUC=0.82 and 0.83 respectively), but was less
accurate in distinguishing Crohn’s disease patients (AUC=0.68).
When we excluded controls from the data and attempted to
distinguish between CD and UC in all IBD patients, we were able
Pediatric IBD Detection by Microbiome Mapping
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95% sensitivity) superior to current noninvasive clinical meth-
ods [13].
The most informative bacterial families in discriminating UC,
CD and Control samples as determined by Kruskal-Wallis test
were the Eubacteriaceae, Bacteroidaceae, and Verrucomicrobia-
ceae (Fig. 6B, also see Fig. S10). Verrucomicrobia were
consistently employed in the classifier because bacteria of this
group were completely absent from UC patients, which tended to
be characterized by Lactobacillales or Bacilli and Gammaproteo-
bacteria.
Steroid treatment could potentially affect the composition of the
microbiota and in turn the accuracy of the classification between
CD and UC. To assess this effect, we limited our analysis to those
patients undergoing steroid therapy. However, we found no
substantial difference in the accuracy of the classification (AUC
=0.73, 40% specificity at 95% sensitivity, Fig. S11) between CD
and UC patients in the steroid subgroup with respect to the totality
of all IBD patients.
Classification in CD or UC performed differently depending on
whether the patient was experiencing active disease or remission,
and surprisingly was more accurate at distinguishing CD and UC
patients in remission (AUC=0.73) than for patients with active
disease (AUC=0.67). This finding suggests that changes in
microbiota composition during acute inflammation may be similar
in both UC and CD, rendering distinction by microbial diversity
more challenging.
Blind Validation with an Independent Patient Sample
Confirms the Accuracy of Supervised Classification
To confirm the general validity of our results, we selected an
independent patient sample of 68 children and young adults.
Following fecal sampling and 16S rRNA sequencing, we applied
SLiME – trained on our initial pediatric cohort – to the new
dataset. Encouragingly, SLiME maintain good performance in
distinguishing IBD patients from controls (AUC =0.84, Fig. S12).
Table S8 illustrates the classification performance of SLiME on
the validation cohort at a chosen threshold.
Figure 2. Taxa significantly associated with IBD. Center panel is a compositional heatmap of the selected taxa for each of the samples in the
pediatric case-control study. Left panel indicates the significance of the association of each taxa with disease state, as measured by the q-value. Right
panel shows a measure of effect size (Cohen’s delta), highlighting in red those taxa which are significantly more prevalent in IBD samples. Bottom
panels show relevant metadata for each sample, including disease activity as measured by PUCAI [32] and PCDAI indices [33].
doi:10.1371/journal.pone.0039242.g002
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Calprotectin
We compared the accuracy of SLiME with the outcome of
the fecal calprotectin test on a portion of our samples from both
the pediatric cohort and the validation cohort, to determine
how our method compared to the most clinically accepted non-
invasive test for IBD. On those 120 samples where we could
obtain calprotectin measurements retrospectively (Table S9), we
found that SLiME could classify the samples as IBD with
comparable accuracy to calprotectin (AUC =0.85 compared to
calprotectin’s AUC of 0.77). Superposing the two ROC curves
(Fig. S13) shows that SLiME is slightly more specific, but
otherwise comparable to calprotectin. Given that calprotectin
levels should be raised in both CD and UC patients, it is not
surprising that SLiME could distinguish CD samples from UC
samples better than calprotectin (AUC 0.69 compared to AUC
0.50 for calprotectin, Fig. S14).
Discussion
Delay in the diagnosis of pediatric IBD is likely due to the non-
specific presentation of the disease. An inexpensive and sensitive
diagnostic tool could reduce this delay by rapidly identifying
patients at high risk for IBD and, therefore, warranting endoscopic
evaluation. In this study, we demonstrated the feasibility of a new
approach to detecting pediatric IBD based on analysis of fecal
microbiota. The sensitivity and specificity of our approach, as
measured by ROC curve analysis, matches or surpasses that of
alternative methods proposed for clinical use.
Two key methodological advances are responsible for improved
performance compared to previous studies. These include the
SLiME software package, which is freely available for public use,
and increased sampling depth, which allows low abundance but
highly informative groups to be sampled. The advantages of
employing machine learning methods to analyze microbiome data
have already been discussed [33]. Compared to clustering
Figure 3. Taxa in the pediatric data set (stool-based) and the Frank et al. data set (tissue-based) agree in their relative abundance.
Mean difference in normalized abundance between IBD samples and control samples is plotted for each taxa. Positive values (x-axis) mean the taxa is
more prevalent in IBD samples, while negative values are associated with taxa more abundant in control samples. Stool-based and tissue-based data
set are differentially colored (dark blue and light blue respectively).
doi:10.1371/journal.pone.0039242.g003
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and extracting pivotal features from large and complex data sets.
SLiME is a pipeline which allows the routine application of these
algorithms to microbiome data.
Previous surveys of microbial diversity in IBD relied on
clustering analyses to differentiate between IBD and non-IBD
samples [18,24,41]. As a result, these studies suffered from poor
sensitivity and, more importantly, did not generate predictive
models that could be employed to distinguish new unlabelled
samples. In this study, we employed SLiME to achieve high
sensitivity as well as high specificity in differentiating IBD samples
from controls. Models generated by SLiME were capable of
classifying unlabelled samples with accuracy, as demonstrated by
the large AUC obtained both after cross-validation and after blind
validation with an independent cohort. Importantly, our approach
was effective across disparate data sets using different sample types,
and processing and sequencing technologies. Finally, we generated
a list of taxa specifically associated with each disease state (active
IBD, remission samples, CD and UC) facilitating biological
interpretation.
Although we succesfully employed specific taxa as predictive
biomarkers, our results indicate that IBD reflects an overall GI
tract dysbiosis rather than the effect of a small number of
pathogenic taxa. This result is in agreement with previous
observations [20,24,40] and suggests that a global community
survey rather than a test for bacterial presence/absence is better
suited to identifying IBD.
Departing from the traditional clustering analysis, a recent and
promising study [25] showed the use of a predictive model in
classifying samples as IBD on the basis of microbial diversity.
However, the same study arised concerns regarding a) the ability
to distinguish UC patients from controls and b) the ability to
discriminate between samples from patients with active disease
and those in remission. Our study answers these questions, and
importantly we report only cross-validated results that should
more closely reflect accuracy in a clinical setting.
Some potential limitations in our study stem from its relatively
small scale. For instance, while we are able to succesfully
distinguish both UC and CD patients, SLiME appears to classify
UC patients more succesfully than CD patients. However, we find
that this difference in performance disappears after downsampling,
confirming that it is probably due to the uneven split between CD
and UC patients in our training cohort.
We also attempted to find correlations between therapeutic
regimens (antibiotics, salicylates, anti-TNF, methotrexate, etc.)
and microbial composition. Unfortunately SLiME was not capable
to differentiate between subgroups with different therapeutic
regimens, most likely due to the broad range of treatments
employed in our cohort and the small number of patients in each
Figure 4. Stratification of patients by activity levels. Overall
microbial diversity as measured by the Shannon Diversity Index. Activity
was assessed on the basis of patient symptoms using PCDAI and PUCAI
clinical indices.
doi:10.1371/journal.pone.0039242.g004
Figure 5. Best features to discriminate by activity levels. Activity
levels are considered simultaneously, employing the Kruskal-Wallis test.
Grey bar indicate the q-value and thus the strength of the association
between the features and the disease state. Color bars indicate the
average percentage of reads for each disease activity level.
doi:10.1371/journal.pone.0039242.g005
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influenced by different therapeutic interventions while differenti-
ating patients with IBD from controls, recruiting a larger number
of patients following similar therapeutic regimens would have
allowed to identify key microbial changes brought about by the
therapy.
It is arguable that both these potential limitations will be
addressed by studies with larger patient samples, better suited to
compare alternatives in disease behaviour and therapeutic
management of IBD. In addition, a cross-sectional study design
on fecal samples taken at the time of diagnosis and before the start
of any therapy, rather than the case-control study we employed,
would allow to estimate more precisely the sensitivity of SLiME
when employed in the general population.
Even though our results demonstrate the potential of the
gastrointestinal microbiome as a diagnostic tool in IBD, further
validation will be necessary before this tool is accepted into clinical
practice. Our comparison between SLiME and calprotectin is
encouraging, insofar as it shows that the two methods have
comparable accuracies on this data set. However, other IBD fecal
biomarkers – such as C-reactive protein, fecal lactoferrin, fecal
calprotectin [10] – and blood biomarkers [42] have shown high
sensitivity in IBD diagnosis. Further comparison of SLiME against
these biomarkers in larger patient samples will allow clinicians to
gauge the relative benefits of each method.
Despite these limitations, our results demonstrate the consider-
able potential of microbiome-based diagnostics in the clinic,
particularly in the case of pediatric patients where diagnosis is
often challenging. Similar approaches could evaluate the efficacy
of novel therapies (e.g. probiotics, antibodies), predict the outcome
of disease and forecast the timings of flare-ups. While not replacing
endoscopy and histological examination as diagnostic tools, we
propose that classification based on microbial diversity can be
included as an effective complementary technique to aid in the
diagnosis of IBD, particularly in pediatric patients.
Materials and Methods
Participants and Ethics
Fecal samples were obtained from 91 children and young adults
with Crohn’s disease, ulcerative colitis, and a control population
composed of children with non-inflammatory conditions of the
gastrointestinal tract (such as functional abdominal pain, consti-
pation and diarrhea). The control population was composed of
patients with symptomatology suggestive of IBD: constipation
(n=9), abdominal pain (n=8), gastroesophageal reflux (n=2),
poor weight gain (n=1), diarrhea (n=1), blood in stool (n=2) and
oropharyngeal dysphagia (n=1). Table 1 shows the patient
demographics. Recruitment was conducted in the clinic or
inpatient hospital wards under a protocol approved by the
Children’s Hospital Committee on Clinical Investigation. Written
informed consent was obtained from patients (if over 18), or from
parents or legal guardian (if patients were minors) for participation
in the study. Written informed consent was obtained from all
participants.
Fecal samples were generally obtained within 4 hours of the
bowel movement, and stool was frozen at 280 degrees C on the
receipt of the sample from the patient. Clinical data were recorded
at the time of sample acquisition including: disease type, disease
location, disease duration, disease activity (as determined by the
Pediatric Crohn’s disease activity index for CD, and the pediatric
ulcerative colitis activity index for UC), and current prescribed
medications.
Figure 6. Discrimination of CD and UC. (A) Above, ROC curve for the classification of CD vs UC in samples where diagnosis of IBD is already
established. Below, ROC curve for the classification of each disease class against all other classes. (B) Strength of association for the best features (q-
value ,0.05) [31] which allow discrimination between CD and UC.
doi:10.1371/journal.pone.0039242.g006
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young adults was selected for blind validation. Table S1 shows the
patient demographics of this additional sample set. Diagnoses for
the control populations, data on disease duration and histological
evidence for both sample sets are contained in Table S2, S3 and
S4 respectively.
DNA Extraction and Sequencing
DNA from stool samples was extracted using the QIAamp DNA
Stool Mini Kit (Qiagen, Inc., Valencia, CA) according to
manufacturer’s instructions. The manufacturer protocol was
altered to accommodate larger volumes of stool and to improve
homogenization using bead-beating techniques at several steps: a)
a minimum of 2 mL of Buffer ASL and 300 mg of stool was used
in the protocol; b) a ratio of 700 uL of Buffer ASL per 100 mg of
stool weight was used for larger volumes using no more than
1500 mg of stool and 10.5 mL of Buffer ASL; c) following the
addition of Buffer ASL to each sample (step #2), 0.70 mm Garnet
Beads (MO BIO Laboratories, Inc., Carlsbad, CA) were added to
the suspension and vortexed for 10 seconds; d) a second bead-
beating was done following the heating of the suspension (step #3)
in 0.1 mm Glass Bead Tubes (MO BIO Laboratories, Inc.,
Carlsbad, CA), and vortexed for 10 minutes.
Extracted DNA was employed for 454 FLX Titaninum
pyrosequencing of PCR-amplified windows of the 16S gene.
Variable region V3–V5 amplification primers were designed
with FLX Titanium adaptors (A adaptor sequence: 59 CCATCT-
CATCCCTGCGTGTCTCCGACTCAG 39; B adaptor se-
quence: 59 CCTATCCCCTGTGTGCCTTGGCAGTCTCAG
39) on the 59 end of the 16S primer sequence: 454B_ 357F (59
CCTACGGGAGGCAGCAG 39) and 454A_barcode_926R (59
CCGTCAATTCMTTTRAGT 39). See Table S5.
Polymerase chain reaction (PCR) mixtures (25 ml) contained
10 ng of template, 16Easy A reaction buffer (Stratagene, La Jolla,
CA), 200 mM of each dNTP (Stratagene), 200 nM of each primer,
and 1.25 U Easy A cloning enzyme (Stratagene). The cycling
conditions for the V3–V5 consisted of an initial denaturation of
95uC for 2 min, followed by 25 cycles of denaturation at 95uC for
40 sec, annealing at 50uC for 30 sec, extension at 72uC for 5 min
and a final extension at 72uC for 7 min. Amplicons were
confirmed on 1.2% Flash Gels (Lonza, Rockland, ME) and
purified with AMPure XP DNA purification beads (Beckman
Coulter, Danvers, MA) according to the manufacturer and eluted
in 25 mLo f1 6low TE buffer (pH 8.0). Amplicons were quantified
on Agilent Bioanalyzer 2100 DNA 1000 chips (Agilent Technol-
ogies, Santa Clara, CA) and pooled in equimolar concentration.
Emulsion PCR and sequencing were performed according to the
manufacturer’s specifications. Sequencing was performed with a
target of 5000 raw reads per sample.
Sanger Sequencing
Polymerase chain reaction (PCR) mixtures (25 ml) contained
10 ng of template, 16Easy A reaction buffer (Stratagene, La Jolla,
CA), 200 mM of each dNTP (Stratagene), 200 nM of each primer
(63f: 59 GCCTAACACATGCAAGTC 39; U1525R: 59 AAG-
GAGGTGWTCCARCC 39), and 1.25 U Easy A cloning enzyme
(Stratagene). The cycling conditions consisted of an initial
denaturation of 95uC for 2 min, followed by 30 cycles of
denaturation at 95uC for 40 sec, annealing at 50uC for 30 sec,
extension at 72uC for 2 min and a final extension at 72uC for
7 min. PCR products were purified with QIAquick PCR
purification kit (QIAGEN, Inc, Valencia, CA) according to the
manufacturer, and size selected on a 1% agarose gel. The gel
bands were purified with QIAquick gel extraction kit (QIAGEN)
according to the manufacturer’s instructions with one modifica-
tion: the gel bands were dissolved at room temperature on a Dynal
Bioteck Rotator (Model RKDYNAL, setting 30, Invitrogen, Life
Technologies, Carlsbad, CA) for 15 minutes. Cleaned amplicons
were cloned (pCR2.1-TOPO vector, TOPO-TA Cloning kit and
electrocompetent cells TOP 10; Invitrogen, Carlsbad, CA) and
sequenced.
Processing Sequencing Samples
Sequences were processed using a data curation pipeline
implemented in MOTHUR [43], which removed sequences from
the analysis if they were less than 200 nt or greater than 600 nt,
had a low read quality score (,25), contained ambiguous
characters, had a non-exact barcode match, or had more than 4
mismatches to the reverse primer sequences (926R). Remaining
sequences were assigned to samples based on barcode matches,
after which barcode and primer sequences were trimmed.
Chimeric sequences were identified using the ChimeraSlayer
algorithm [44], and reads were classified with the MSU RDP
classifier v2.2 [45] using the taxonomy maintained at the
Ribosomal Database Project (RDP 10 database, version 6). After
processing, the resulting sequencing depth was 26906898 (median
6 median abs. deviation) reads per sample.
Synthetic Learning in Microbial Ecology (SLiME)
Using a set of training data, supervised learning algorithms can
be trained to classify each microbiota sample into distinct classes
(eg. IBD/non-IBD) based on a defined set of features (eg. the
relative abundance of each OTU). We first assigned each sequence
in the data set to a taxonomical group using the RDP Naive
Bayesan classifier [46]. For each sample we then calculated the
relative abundance of each taxa with respect to the total number of
sequences in each sample. We then trained a random forest (RF)
classifier (R-project implementation [29,47] ) to assign the class
(IBD or non-IBD) based on the relative sequence abundances in
every taxa. We used ten-fold cross-validation to compute accuracy
of the classifier, where training of the classification algorithm
employs a random 90% of the available patients and the
performance of the generated model is tested on the remaining
10% of patients.
Fecal Calprotectin Test
Calprotectin was assayed using the calprotectin ELISA kit
(Bu ¨hlmann Laboratories/ALPCO Diagnostics) and followed the
manufacter testing protocol. Samples were shaken on an orbital
shaker at 600 rpm. ELISA plates were read with the Varioskan
(Thermo Scientific). SkanIT software (Thermo Scientific) was used
to fit the standard curve using four parameter curve fitting.
Statistical Analyses
Several approaches can be used to identify the features which
were most important to the classification task: a) a priori
statistical tests, b) statistics intrinsic to the supervised learning
algorithm or c) iterative measures of the importance of each
variable [48]. To minimize computational complexity and
exclusively for the purpose of visualization we selected taxa
independently from the classification task and chose to employ
an a priori statistical test. Taxa were tested for significant
association with disease state by means of non-parametric
Kruskal-Wallis test, which does not include an assumption of
normality. Multiple p-values were then converted to q-values, by
FDR adjustment [36] and a significance threshold was chosen
between q-value ,0.01 or q-value ,0.05 by estimating the p0
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[36] for details). In the case of IBD/control, CD/UC and
activity classification, features individuated by Kruskal-Wallis
test were largely overlapping with the list of most discriminative
features obtained by iterative measures and intrinsic measures
(data not shown). No feature selection or other dimensionality
reduction was used in the classification task.
Receiver operating characteristic analysis was used to evaluate
the classification algorithms across a range of possible disease
prevalences. Reported AUC values are median AUC values
resulting from 3 repetitions of 10-fold cross validations.
All calculations were performed in R [47] and plots were
generated in R using the ggplot library [49].
Supporting Information
Figure S1 Patients are classifiable as IBD and non-IBD
with a variety of supervised learning algorithms. ROC
curves for SVM, Bagging (decision tree as base classifier), Stacking
(decision tree as base classifier) and RFs are shown.
(PDF)
Figure S2 Sequencing technology does not significantly
influence classification accuracy. ROC curves for active
IBD vs. control classification in ten samples where sequencing was
repeated by Sanger methods and yielded the same area under the
curve.
(PDF)
Figure S3 Relative abundance of each discriminatory
feature compared to the sequencing depth of other IBD
microbiota surveys. Two vertical lines indicate the minimum
detectable abundance in the Frank et al. study (right) and the
Willing et al. study (left). Due to low sequencing depth, the Frank
et al. survey could have detected only 13 of the features considered
discriminatory for classification (right vertical line).
(PDF)
Figure S4 FDR adjustment of Kruskal-Wallis p-values
for those features which best discriminate between IBD
samples and control samples. (Top-left) The expected
proportion of false positive samples (p0) is estimated by fitting.
(Top-right) A plot of the calculated q-values versus the initial p-
values. (Bottom-left) The number of significant tests for every given
q-value cut-off. (Bottom-right) The number of expected false
positives for a given number of significant tests considered.
(PDF)
Figure S5 Taxa in the pediatric data set (stool-based)
and the Frank et al. data set (tissue-based) vary in their
importance as features. Best features - as determined by the
RandomForest algorithm - applied to the pediatric data set are
used to classify the Frank et al. data set. The importance of each
feature - calculated as the decrease in accuracy of the algorithm
when the feature is not used - is plotted for both studies.
Noticeably, feature at the genus level are far more important in the
pediatric data set than when used on the Frank et al. data set. This
may reflect the greater depth of sequencing (see Figure S2).
(PDF)
Figure S6 FDR adjustment of Kruskal-Wallis p-values
for those features which best discriminate between
levels of IBD activity. (Top-left) The expected proportion of
false positive samples (p0) is estimated by curve fitting. (Top-right)
A plot of the calculated q-values versus the initial p-values.
(Bottom-left) The number of significant tests for every given q-
value cut-off. (Bottom-right) The number of expected false
positives for a given number of significant tests considered.
(PDF)
Figure S7 Features that show the greatest difference
between active and inactive state in the pediatric case-
control study. All features with significant association (q-value
,0.05, see Figure S12){Storey,2003} to either active disease or
remission are shown. Grey bars indicate the q-value of each taxon,
heat maps describe the median normalized abundance in each
sample. The right panel indicates the effect size and highlights in
red the taxa which are prevalent in active samples.
(PDF)
Figure S8 FDR adjustment of Kruskal-Wallis p-values
for those features which best discriminate between
active IBD samples and inactive IBD samples. (Top-left)
The expected proportion of false positive samples (p0) is estimated
by curve fitting. (Top-right) A plot of the calculated q-values versus
the initial p-values. (Bottom-left) The number of significant tests
for every given q-value cut-off. (Bottom-right) The number of
expected false positives for a given number of significant tests
considered.
(PDF)
Figure S9 Antibiotic therapy reduces overall microbial
diversity. Box plot showing the distribution of Shannon diversity
indices for all patients undergoing antibiotic therapy, compared to
the patients with IBD and without antibiotics, as well as controls.
(PDF)
Figure S10 FDR adjustment of Kruskal-Wallis p-values
for those features which best discriminate between CD
samples and UC samples. (Top-left) The expected proportion
of false positive samples (p0) is estimated by curve fitting. (Top-
right) A plot of the calculated q-values versus the initial p-values.
(Bottom-left) The number of significant tests for every given q-
value cut-off. (Bottom-right) The number of expected false
positives for a given number of significant tests considered.
(PDF)
Figure S11 ROC curve for the CD vs UC classification in
the steroid-treated subgroup. The performance in this subset
of the cohort is comparable to the totality of IBD patients.
(PDF)
Figure S12 Blind validation of a SLiME model -
previously trained on our pediatric cohort - applied to
an independent set of fecal samples from 77 patients.
ROC curve shows that high sensitivity and high specificity are
maintained across a range of disease prevalences.
(PDF)
Figure S13 Comparison of SLiME and fecal calprotectin
assay. The two assays have comparable efficacy in distinguishing
IBD patients from control when applied to all samples in the
training and validation cohorts for which calprotectin could be
measured (n=120).
(PDF)
Figure S14 Comparison of SLiME and fecal calprotectin
assay. SLiME is slightly superior in distinguishing CD from UC
samples, when applied to all CD and UC samples (n=90) in the
training and validation cohorts for which calprotectin could be
measured.
(PDF)
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(RTF)
Table S2 Control patients’ diagnose
(RTF)
Table S3 Disease Duration at Time of Sample Acquisi-
tion
(RTF)
Table S4 Histological evidence of disease at diagnostic
colonoscopy
(RTF)
Table S5 454 barcodes and primers
(RTF)
Table S6 Confusion matrix for the SLiME classification
of the pediatric training cohort. Sensitivity 87.6%. Specificity
45.8%. Note this is only one possible cutoff value. Different
sensitivity and specificity can be obtained by appropriately tuning
the cutoff.
(RTF)
Table S7 Confusion matrix for the SLiME classification
of the training cohort on the subset of patient with
clinically active disease at the time of sampling.
Sensitivity 82.5%. Specificity 75%. Note this is only one possible
cutoff value. Different sensitivity and specificity can be obtained by
appropriately tuning the cutoff.
(RTF)
Table S8 Confusion matrix for the blind validation of
the SLiME classifier on an independent validation
cohort. Sensitivity for IBD vs controls is 94.5%, while specificity
is 46.1%. Note this is only one possible cutoff value. Different
sensitivity and specificity can be obtained by appropriately tuning
the cutoff.
(RTF)
Table S9 Summary of calprotectin assay results
(RTF)
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